fda declaratory order semaglutide shortage resolved feb 21 2025 US Employs Familiar Strategy In Ending Novo's Wegovy, Ozempic FDA's Crackdown on Compounded GLP-1
Description
[DOI] [PubMed] [Google Scholar] 93.Bareti M., Kuec V., Pavli-Renar I
For patients whose genetics or prior response suggest GIP pathway sensitivity, tirzepatide unlocks additional weight loss
Similar patterns emerge with tirzepatide, though longer-term discontinuation data remains limited
Dubath C, Piras M, Gholam M, et al
Mehra et al., 2022
